Skip to main content
. 2016 Dec 1;7(6):1140–1151. doi: 10.1016/j.stemcr.2016.11.001

Figure 5.

Figure 5

Panel of SUMO Inhibitors Repressed CD44 and Tumorigenesis

(A) A panel of SUMO inhibitors was tested for the ability to repress CD44: vehicle (VEH); ginkgolic acid at 10 μM (GA10) or 50 μM (GA50); PYR-41 at 10 μM (PYR10) or 50 μM (PYR50); and NSC-207895 at 10 μM (NSC10). Relative CD44 protein: VEH, 1.0; GA10, 1.17; GA50, 0.22; PYR10, 0.77; PYR50, 0.14; NSC10, 0.77.

(B) Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (∗p < 0.05).